Impaired monocyte cytokine production in critically ill patients with acute renal failure. 2004

Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
Maine Medical Center, Portland, Maine 04102, USA. himmej@mmc.org

BACKGROUND Plasma levels of pro- and anti-inflammatory cytokines are predictive of mortality in patients with acute renal failure (ARF). Anti-inflammatory strategies are postulated to be beneficial in treatment. However, there are few studies simultaneously examining monocyte cytokine production and plasma cytokine levels in patients with ARF. METHODS Study populations consisted of 20 critically ill patients with ARF, 19 critically ill patients without ARF (CRIT ILL), 28 healthy subjects (HS), 19 patients with chronic kidney disease (CKD), and 15 patients with end-stage renal disease (ESRD). Monocyte intracellular content of interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-8, and tumor necrosis factor-alpha (TNF-alpha) was determined by flow cytometry in whole blood. Plasma interleukin 6 and TNF-alpha concentrations were determined by enzyme-linked immunosorbent assay (ELISA). RESULTS At baseline, there were no differences in intracellular monocyte cytokine levels between groups. After lipopolysaccaride stimulation, monocyte production of IL-1beta, TNF-alpha, and IL-6 in ARF patients was reduced by 41%, 84%, and 45%, respectively, compared to healthy subjects (P < 0.01 in each case), and similarly reduced compared to CKD and ESRD patients, and were similar to CRIT ILL patients. Plasma IL-6 levels were significantly higher in ARF patients than healthy subjects, CKD, and ESRD patients (all P < 0.001). CONCLUSIONS Critically ill patients with acute renal failure have impaired monocyte cytokine production and elevated plasma cytokine levels in a pattern that closely resembles critically ill patients without ARF, and that is dissimilar to CKD and ESRD patients.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
January 2007, Anesteziologiia i reanimatologiia,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2005, Ugeskrift for laeger,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
February 2007, Ugeskrift for laeger,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
January 2010, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
October 1999, Intensive care medicine,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2003, JAMA,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2003, JAMA,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2003, JAMA,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2003, JAMA,
Jonathan Himmelfarb, and Phuong Le, and Jennifer Klenzak, and Stephanie Freedman, and M Elizabeth McMenamin, and T Alp Ikizler, and
March 2003, JAMA,
Copied contents to your clipboard!